| Literature DB >> 34874461 |
Johanna Falkenhorst1, Rainer Hamacher1, Sebastian Bauer2.
Abstract
Retroperitoneal soft tissue sarcomas represent extreme challenges for interdisciplinary treatment teams. The sarcoma-specific experience of surgeons has the greatest impact on the survival of patients; however, too many patients still die despite optimal local treatment. The role of chemotherapy is undisputed only for patients with highly malignant bone sarcomas or rhabdomyosarcomas. For soft tissue sarcomas in adult patients, especially liposarcomas and leiomyosarcomas, the evidence situation is very unsatisfactory. This overview article discusses the complex data situation and controversial aspects that are relevant for current treatment decisions in interdisciplinary treatment teams.Entities:
Keywords: Chemotherapy; Evidence; Leiomyosarcoma; Liposarcoma; Sarcoma
Mesh:
Year: 2021 PMID: 34874461 DOI: 10.1007/s00104-021-01539-x
Source DB: PubMed Journal: Chirurg ISSN: 0009-4722 Impact factor: 0.955